AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Orion Oyj

Board/Management Information Mar 26, 2019

3232_rns_2019-03-26_71664624-5f51-4076-b052-57629f4b1a59.html

Board/Management Information

Open in Viewer

Opens in native device viewer

Disclosure 370158

Orion - Other information disclosed according to the rules of the Exchange

Orion Corporation: Organising meeting of the Board of Directors

Orion Corporation Stock Exchange Release 26 March 2019 at 5.30 p.m. EET Orion Corporation: Organising meeting of the Board of Directors In its organising meeting, the Board of Directors of Orion Corporation, which was elected today by the Annual General Meeting of the Shareholders, has elected Timo Maasilta as Vice Chairman. The compositions of the Board committees were decided to be as follows: Remuneration Committee: Heikki Westerlund, Chairman Timo Maasilta Mikael Silvennoinen Audit Committee: Mikael Silvennoinen, Chairman Pia Kalsta Ari Lehtoranta Eija Ronkainen R&D Committee: Hilpi Rautelin, Chairman Pia Kalsta Ari Lehtoranta Timo Maasilta Eija Ronkainen Mikael Silvennoinen Heikki Westerlund The members to the Nomination Committee were elected on 30 October 2018 as stated in the Stock Exchange Release on the same day. The Board of Directors has assessed the independence of its members and concluded that all the members are independent of the company and its significant shareholders. Orion Corporation Timo Lappalainen Olli Huotari President and CEO Senior Vice President, Corporate Functions Contact person: Olli Huotari, Senior Vice President, Corporate Functions Phone +358 50 966 3054 Publisher: Orion Corporation Communications Orionintie 1A, FI-02200 Espoo, Finland Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2018 amounted to EUR 977 million and the company had about 3,200 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki. For more information, go to www.orion.fi/en []

Talk to a Data Expert

Have a question? We'll get back to you promptly.